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Background and purpose — It is unclear whether metal parti-
cles and ions produced by mechanical wear and corrosion of hip 
prostheses with metal-on-metal (MoM) bearings have systemic 
adverse effects on health. We compared the risk of heart failure 
in patients with conventional MoM total hip arthroplasty (THA) 
and in those with metal-on-polyethylene (MoP) THA.
Patients and methods — We conducted a retrospective cohort 
study using data from the Australian Government Department of 
Veterans’ Affairs health claims database on patients who received 
conventional THA for osteoarthritis between 2004 and 2012. 
The MoM THAs were classified into groups: Articular Surface 
Replacement (ASR) XL Acetabular System, other large-head 
(LH) (> 32 mm) MoM, and small-head (SH) (≤ 32 mm) MoM. The 
primary outcome was hospitalization for heart failure after THA.
Results — 4,019 patients with no history of heart failure were 
included (56% women). Men with an ASR XL THA had a higher 
rate of hospitalization for heart failure than men with MoP THA 
(hazard ratio (HR) = 3.2, 95% CI: 1.6–6.5). No statistically sig-
nificant difference in the rate of heart failure was found with the 
other LH MoM or SH MoM compared to MoP in men. There was 
no statistically significant difference in heart failure rate between 
exposure groups in women. 
Interpretation — An association between ASR XL and hos-
pitalization for heart failure was found in men. While causality 
between ASR XL and heart failure could not be established in this 
study, it highlights an urgent need for further studies to investi-
gate the possibility of systemic effects associated with MoM THA.

It has been reported that more than 1 million metal-on-metal 
(MoM) bearing total hip arthroplasties (THAs) have been per-
formed globally (Kwon et al. 2014). While MoM hips were 
generally recommended by companies for young and active 
patients, these devices became popular among orthopedic sur-
geons and were used in a wide range of patients. The advan-
tage of the MoM hip design, which permitted the use of a large 
femoral head, was a lower risk of dislocation and an improved 
range of movement compared to other bearings.
MoM hip prostheses with components made of cobalt-
chromium alloys are known to produce high levels of metal 
particles and metal ions from wear and corrosion (Lavigne 
et al. 2011, Chang et al. 2013, Jantzen et al. 2013). Resul-
tant damage to local soft tissues and periprosthetic bone and 
(consequently) increased rates of revision surgery have often 
been reported (Pandit et al. 2008, Langton et al. 2010, Fary et 
al. 2011, Sampson and Hart 2012, Hug et al. 2013, Langton 
et al. 2013). The revision rates vary according to the class of 
MoM prosthesis (Graves et al. 2011). For example, conven-
tional stemmed large-head (LH) MoM (> 32 mm diameter) 
prostheses have the highest rate of revision compared to both 
small-head (SH) MoM (≤ 32 mm diameter) and resurfacing 
hip replacement (AOANJRR 2015). 
The risk of revision has also varied within class. The Aus-
tralian Orthopaedic Association National Joint Replacement 
Registry (AOANJRR) has reported that the cumulative per-
centage of revisions at 7 years for the 13 most commonly used 
conventional LH MoM ranges from 4.3% to 37% (AOANJRR 
SR 2015). The one with the highest proportion of revisions 
was the Articular Surface Replacement (ASR) XL Acetabular 
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System (DePuy). This device was withdrawn from the market 
in Australia in 2009, and was subject to a worldwide recall 
in 2010. The high rate of revision for this prosthesis is due 
mainly to metal ion-related pathology, and this is almost cer-
tainly related to design and manufacturing differences com-
pared to other LH MoM prostheses. 
In addition to the local effects reported, there has been 
increasing concern that the dissemination of wear particles 
and increased blood levels of metal ions, especially cobalt, 
may be associated with systemic adverse effects on health 
(Campbell and Estey 2013). There is no doubt that high levels 
of serum cobalt are associated with systemic adverse effects. 
This has been known since the 1960s when there was an 
epidemic of heart failure in people who drank beer contain-
ing cobalt, which was added as a foam stabilizer (Morin and 
Daniel 1967). 
To date, there have been a number of case reports of sus-
pected systemic adverse effects on health following the use 
of MoM THA (Cheung et al. 2016, Zywiel et al. 2016). In 
a case study of a patient with bilateral ASR XL  prostheses 
who developed heart failure in both native heart and trans-
planted heart, Allen et al. (2014) found signs of mitochondrial 
injury and elevated cobalt levels in heart tissue, supporting the 
diagnosis of cobalt-induced cardiomyopathy. There have also 
been case reports of neuropathies (auditory, optic, polyneu-
ropathy), depression, cognitive impairment, hypothyroidism, 
and renal function impairment associated with MoM bearings 
(Tower 2010, Mao et al. 2011, Cohen 2012, Machado et al. 
2012, Devlin et al. 2013, Gessner et al. 2015). Furthermore, 
a cross-sectional study of patients with resurfacing MoM hip 
arthroplasties identified reduced cardiac ejection fraction in 
asymptomatic patients who had cobalt levels above the cobalt 
levels in patients in a matched reference group, but below 
what was previously thought to be the threshold concentration 
for prosthesis malfunction (Prentice et al. 2013). 
Although current evidence suggests that MoM THA may be 
associated with detrimental systemic health effects, the inci-
dence of this remains unknown. The aim of this study was to 
determine whether conventional MoM THA is associated with 
a higher rate of developing heart failure compared to a refer-
ence cohort who received THA with the commonly used bear-
ing of metal-on-polyethylene (MoP). An additional aim was 
to determine whether MoM THA was associated with higher 
mortality than in the reference cohort. 
Methods
Study sample
We conducted a retrospective cohort study using data from 
the Australian Government Department of Veterans’ Affairs 
(DVA) health claims database. The database contains compre-
hensive data on prescription medicines, hospital admissions 
in both public and private hospitals, procedures, and medical 
devices for all Australian veterans and their spouses. The data-
base has a current treatment population of 233,800 veterans 
with a median age of 82 years. Veterans, widowers/widows, or 
dependents of veterans were included if they had full entitle-
ment to all DVA services. The DVA provides funding for all 
treatments related to all medical conditions in these patients.
The study sample consisted of patients who underwent pri-
mary THA for treatment of osteoarthritis in private hospitals 
between January 1, 2004 and December 31, 2012. Primary 
THA procedures were identified using the Australian Classifi-
cation of Health Interventions (ACHI/ICD-10-AM) procedure 
codes 49318-00 and 49319-00. For those patients who under-
went more than 1 primary hip procedure during the study 
period, only the initial primary THA undertaken in the study 
period was used in the analysis.
Patients who had a record of hospitalization for heart failure 
(either primary or any secondary discharge diagnoses, ICD-
10-AM codes I50.0–I50.9) in the year prior to the THA were 
excluded (n = 273). In addition, those who were dispensed 
heart failure medication in the year before were also excluded 
(n = 762) (Table 1). Specification of heart failure medication 
was based on the National Heart Foundation of Australia and 
Cardiac Society of Australia and New Zealand guidelines 
for management of chronic heart failure (2011) and included 
angiotensin-converting-enzyme inhibitor with a loop diuretic, 
heart-specific beta blocker, spironolactone, or loop diuretics 
with an angiotensin II receptor blocker. 
Exposure of interest
Exposure groups were created based on the THA bearing sur-
face used in the primary procedure. The bearing surface was 
ascertained by matching product codes associated with the hip 
procedure with the Australian Government’s Prosthesis List 
(2016), which contains a unique billing code for individual 
prostheses. As the MoP bearing is the most common articula-
tion in THA, this was used as the comparator for MoM THAs. 
Based on the literature on varying performance and revision 
rates for different MoM types (Graves et al. 2011), 3 groups of 
MoM THAs of interest were identified: ASR XL, which has 
the highest revision rate of all large-head (LH) MoM THAs 
(AOANJRR SR 2015), other LH MoM THAs, and all small-
head (SH) MoM THAs. 
Outcome of interest
The main outcome of interest was first hospitalization for 
heart failure after the primary THA (ICD-10-AM codes I50.0–
I50.9 as primary discharge diagnosis). A secondary outcome 
was all-cause mortality. A sensitivity analysis was performed 
for the primary analysis, in which we identified heart failure 
events as hospitalizations with the specified discharge diagno-
sis codes as either a primary or a secondary diagnosis. 
Effect modifiers and confounders
Patient age and sex are associated with development of heart 
4 Acta Orthopaedica 2017; 88 (1): 2–9
failure. Age and sex were therefore evaluated as confounders 
and as effect modifiers. Only sex was identified as an effect 
modifier for the primary outcome (hospitalization for heart 
failure as a primary diagnosis), so all analyses were stratified 
by sex. Other covariates considered as possible confounders 
included type of fixation of the prosthesis (cementless/cement) 
and comorbidities at baseline, identified by RxRisk-V (Sloan 
et al. 2003). RxRisk-V is a prescription based comorbidity 
measure with 45 disease categories; it has been validated as a 
measure of comorbidity burden (Vitry et al. 2009) (Appendix 
1, see Supplementary data). 
Statistics
Medians, interquartile ranges, frequencies, and proportions 
were used to describe the study sample. Survival analyses 
were conducted for time to first hospitalization for heart fail-
ure and for time to death after the primary THA. Patients 
were censored at the time of death, revision of the hip pros-
thesis, or admission to hospital for a second primary hip pros-
thesis. Cumulative incidence curves were used to describe 
the estimated cumulative probabilities of heart failure strati-
fied by exposure groups and sex, accounting for informative 
censoring. Cox proportional hazards (PH) models were used 
to estimate the cause-specific hazard ratio (HR) for hospi-
talization for heart failure by exposure group. Time at risk 
of hospitalization for heart failure was measured from day 
of discharge from the hospital after the THA operation until 
first hospital admission for heart failure or the end of the 
study period (June 30, 2014). The Cox PH model was used 
to examine all-cause mortality by exposure group, stratified 
by sex and adjusted for age and comorbidities. Confounders 
were included, based on clinical knowledge and bias assess-
ment using the method for directed acyclic graphs (DAG) 
outlined by Shrier and Platt (2008) and a DAG graphical 
tool (Textor et al. 2011) combined with a change in estimate 
approach. The assumption of proportional hazards for the 
Cox PH model was confirmed using interactions with time 
and covariates. SAS version 9.4 was used for all analyses. 
Any 2-tailed p-value of less than 0.05 was considered to be 
statistically significant.
Results
4,019 patients were included in the study; 3,546 (88%) 
received MoP prostheses, 121 (3%) received ASR XL pros-
theses, 231 (6%) received other LH MoM prostheses, and 121 
(3%) received SH MoM prostheses. Baseline characteristics 
Table 1. Characteristics of study sample according to hip bearing surface and sex, 2004–2012
 Men Women
Bearing surface MoP ASR XL LH MoM  SH MoM MoP ASR XL LH MoM  SH MoM
    (> 32 mm) (≤ 32 mm)   (> 32 mm) (≤ 32 mm)
Pre-exclusion cohort:  Men (n = 2,384)   Women (n = 3,213)
 Total patients, n (%) 2,026 (85) 87 (3.6) 171 (7.2) 100 (4.2) 2,907 (90.5) 79 (2.5) 159 (5) 68 (2.1)
 Heart failure medication a    268 12   18   11    413 12   21   7
 Heart failure admission a    122   3     8     2    126   3     7   2
Study cohort:  Men (n = 1,764)   Women (n = 2,255)
 Total patients, n (%) 1,502 (85.1) 63 (3.6) 124 (7) 75 (4.3) 2,044 (90.1) 58 (2.6) 107 (4.7) 46 (2)
 Age, median, years 82.3 81.6 77.8 77.3 82.2 80.6 80.2 79.4
    IQR 75.6–85.6 68.3–85.1 64.2–83.2 69.9–82.7 78.9–85.2 77.9–83.6 76.3–84.5 76.3–81.2
 Age groups, n (%)         
    < 55   12 (0.8)   0 (0)   7 (6)   2 (3)        1 (0)   0 (0)   0 (0)   1 (2)
    55–64 156 (10.4) 13 (21) 27 (22) 20 (27)      13 (0.6)   1 (2)   6 (6)   2 (4)
    65–74 193 (12.8)   8 (13) 21 (17) 13 (17)    190 (9.3)   5 (9) 14 (13)   5 (11)
    75–84 705 (46.9) 26 (41) 46 (37) 36 (48) 1,292 (63.2) 40 (69) 64 (60) 35 (76)
    ≥ 85 436 (29) 16 (25) 23 (19)   4 (5)    548 (26.8) 12 (21) 23 (21)   3 (7)
 Fixation, n (%)         
    Uncemented 605 (40.3) 61 (97) 73 (59) 69 (92)    656 (32.1) 53 (91) 61 (57) 32 (70)
    Cemented 897 (59.7)   2 (3) 51 (41)   6 (8) 1,388 (67.9)   5 (9) 46 (43) 14 (30) 
 Comorbidities b, 
    median (IQR) 4.0 (3.0–6.0) 4.0 (2.0–6.0) 4.0 (3.0–6.0) 4.0 (2.0–5.0) 5.0 (3.0–6.0) 4.0 (2.0–6.0) 5.0 (3.0–6.0) 4.0 (1.0–6.0)
    n (%)          
       0 75 (5)   5 (8)   5 (4)   5 (7)    132 (6.5)   3 (5)   4 (4)   6 (13)
       1 108 (7.2)   6 (9)   8 (6)   9 (12)    111 (5.4)   7 (12)   1 (1)   6 (13)
       2 181 (12.1)   6 (9) 16 (13)   9 (12)    185 (9.1)   6 (10) 10 (9)   5 (11)
       3 204 (13.6) 11 (18) 26 (21) 10 (13)    281 (13.7)   9 (16) 18 (17)   4 (9)
       ≥ 4 934 (62.1) 35 (56) 69 (56) 42 (56) 1,335 (65.5) 33 (57) 74 (69) 25 (54)
MoP: metal-on-polyethylene; ASR: Articular Surface Replacement; LH MoM: large-head metal-on-metal; SH MoM: small-head metal-on-metal; 
IQR: interquartile range.
a Record of admission/dispensed medication in the year prior to the primary THA.
b Comorbidities based on RxRisk-V.
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of the cohorts are presented in Table 1 and baseline RxRisk-V 
in Appendix 1 (see Supplementary data).
Crude incidences of the main and secondary outcomes are 
presented in Table 2. In men, the proportion who were hospi-
talized with a primary diagnosis of heart failure was 10/63, 
10/124, 4/75, and 114/1,506 in patients who had ASR XL 
prostheses, other LH MoM prostheses, SH MoM prostheses, 
and MoP prostheses, respectively. For women, the proportion 
with heart failure was 2/58  with ASR XL, but otherwise the 
incidence of heart failure was similar to that in men (6/107 
with LH MoM, 2/46 with SH MoM, and 162/2,044 with MoP).
The cumulative probability of hospitalization for heart fail-
ure after receiving a THA is shown in Figures 1 and 2. For 
men, there was a higher rate of hospitalization for heart failure 
with ASR XL than with MoP (hazard ratio (HR) = 3.2, 95% 
CI: 1.6–6.5) (Table 3). Compared to MoP, there was no statis-
tically significant difference in the rate of hospitalization for 
heart failure in men who received SH MoM or other LH MoM 
THA. Also, compared to MoP there was no significant differ-
ence in hospitalization rates for heart failure in women with 
ASR XL (HR = 0.5, 95% CI: 0.1–1.9), or with any other type 
of MoM THA (Table 3). 
The results were similar to those from the main analysis in 
the sensitivity analysis, in which both primary and secondary 
diagnoses were used to identify hospitalizations for heart fail-
ure (Appendix 2, see Supplementary data). 
Mortality was high for all bearing groups, and higher in men 
than in women (Table 2). Compared to MoP bearings, no sta-
tistically significant difference in mortality was observed for 
any of the MoM bearings (Table 3). 
Discussion 
To our knowledge, this is the first observational cohort study 
to identify an association between an adverse systemic health 
Table 2. Incidence of hospitalization for heart failure, death, revision surgery, and second total hip replacement (THR) according to hip 
bearing surface and sex
 Men Women
Bearing surface MoP ASR XL LH MoM  SH MoM MoP ASR XL LH MoM  SH MoM
    (> 32 mm) (≤ 32 mm)   (> 32 mm) (≤ 32 mm)
  (n = 1,502) (n = 63) (n = 124) (n = 75) (n = 2,044) (n = 58)  (n = 107)  (n = 46)
Heart failure hospitalization 
 primary diagnosis, n (%) 114 (7.6) 10 (16) 10 (8)   4 (5) 162 (7.9)   2 (3)   6 (6)   2 (4)
 primary or secondary diagnosis, n (%) 270 (18.0) 18 (29) 18 (15) 12 (16) 322 (15.8) 11 (19) 13 (12)   5 (11)
Death, all causes, n (%) 558 (37.2) 26 (41) 34 (27) 22 (29) 544 (26.6) 11 (19) 23 (22) 11 (24)
Revision surgery, n (%)   79 (5.3)   5 (8) 12 (10)   7 (9)   80 (3.9)   4 (7)   8 (8)   3 (7)
Second primary THR, n (%) 146 (9.7)   9 (14) 13 (11) 11 (15) 199 (9.7) 12 (21) 11 (10)   7 (15)
Follow-up, median (IQR) a, years 6.8 7.2 6.7 7.4 6.5 6.6 6.3 9.0
 IQR 6.4–7.2 6.4–8.0 6.1–7.1 6.3–8.6 6.3–6.7 6.1–7.3 6.0–7.1 8.5–9.4
See Table 1 for abbreviations.
a Censored: death, hospitalization for heart failure, second total hip arthroplasty, and revision. 
Figure 1. Cumulative probabilities of hospitalization for heart failure in 
men. See Table 1 for abbreviations.
Figure 2. Cumulative probabilities of hospitalization for heart failure in 
women. See Table 1 for abbreviations.
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effect, in this case hospital admission for heart failure, and the 
use of MoM THA. This effect was only observed with 1 type 
of prosthesis (ASR XL (DePuy)) and was only evident in men. 
Based on our results, we estimate that after 3 years 1 addi-
tional hospitalization for heart failure would have occurred for 
every 11 (95% CI: 6–109) men treated with an ASR XL pros-
thesis rather than a MoP prosthesis.
The higher rate of hospitalization for heart failure with ASR 
XL only is consistent with previous research showing that the 
ASR XL has the highest revision rate of any LH MoM pros-
thesis (AOANJRR SR 2015). The higher revision rate with the 
ASR XL has been attributed to a higher occurrence of metal-
related pathology compared to similar prostheses (AOANJRR 
SR 2015). The identification of a higher rate of heart failure 
that is specific to this high-risk prosthesis—and not to other 
MoM THAs—supports the idea that the association between 
heart failure and the use of the ASR XL is real. An impor-
tant possible implication of these findings is that other MoM 
prostheses may also be associated with an increased risk of 
developing heart failure as time progresses. 
There are a number of possible explanations as to why the 
higher heart failure rate was only observed in men. It is known 
that the risk of heart failure increases with age, and that men 
have a higher incidence (Bui et al. 2011). It has been reported 
that in the DVA population, men have higher rates of hospi-
talization than women, which is consistent with the idea that 
most women with full-entitlement benefits are likely to be war 
widows with no service-related injuries and diseases (Lloyd 
and Anderson 2008). In our study cohort, mortality was higher 
for men than for women in all exposure groups. Hence, the 
sex difference may reflect that the male cohort in this study 
is a more vulnerable group and as such was more susceptible 
to development of heart failure following exposure to MoM 
prostheses than the female cohort. This is consistent with our 
results, where the hospitalization rate for heart failure was 
statistically significantly higher for men with MoM hips than 
for women with MoM hips, whereas there was no significant 
sex difference in the rate of hospitalization for heart failure 
in patients with MoP hips (data not shown). In the Quebec 
heart failure epidemic, most of the heart failures reported after 
drinking beer with added cobalt occurred in men (Morin et 
al. 1967, Kesteloot et al. 1968, Sullivan et al. 1969, Alexan-
der 1972). Although it is possible that this phenomenon is due 
to preferential exposure or other contributory factors such as 
poor nutritional status, the possibility of greater male suscep-
tibility to the toxic effects of cobalt remains. 
While we were unable to associate the occurrence of heart 
failure directly with raised serum cobalt ion levels in this 
study, our identification of higher rate of admission for heart 
failue being confined to the prosthesis that was most at risk is 
strong circumstantial evidence of a link to raised serum cobalt. 
Patients with the ASR XL prosthesis and also other large-head 
MoM THAs have been identified as having raised blood levels 
of cobalt ions (Hart et al. 2011, Gill et al. 2012, Chang et al. 
2013, Hartmann et al. 2013, Jantzen et al. 2013, Randelli et al. 
2013), with the levels normalizing after the hip prostheses had 
been removed (Allen et al. 2014). Blood levels of cobalt are 
related to wear rate and corrosion of the prosthesis (Vendittoli 
et al. 2011, Hart et al. 2013). An increase in revision has been 
associated with increasing blood levels of cobalt (Hart et al. 
2014). In patients with an ASR XL THA, a positive correlation 
between blood levels of cobalt and femoral head size has been 
reported (Langton et al. 2011). The ASR XL THA has also 
been associated with a higher rate of revision than other LH 
MoM prostheses (de Steiger et al. 2011), indicating a greater 
problem with metal products in the ASR XL prosthesis.
We found no statistically significant difference in rates of 
hospitalization for heart failure between patients with other 
Table 3. Association between bearing type and heart failure and death in men and women 
 Men Women   
  Crude HR Adjusted a HR  Crude HR Adjusted b HR 
  (95% CI) (95% CI) p-value (95% CI) (95% CI) p-value
Heart failure hospitalization c – primary diagnosis
 MoP Reference Reference  Reference Reference 
 ASR XL 2.28 (1.19–4.37) 3.21 (1.59–6.47) 0.001 0.47 (0.12–1.88) 0.46 (0.12–1.88) 0.3
 LH MoM (> 32 mm) 0.88 (0.43–1.81) 1.20 (0.58–2.48) 0.6 0.75 (0.33–1.70) 0.89 (0.39–2.02) 0.8
 SH MoM (≤ 32 mm) 0.52 (0.16–1.63) 0.94 (0.29–3.06) 0.9 0.44 (0.11–1.76) 0.67 (0.17–2.73) 0.6 
Death, all causes       
 MoP Reference Reference  Reference Reference 
 ASR XL 0.95 (0.64–1.41) 1.15 (0.76–1.72) 0.5 0.65 (0.36–1.19) 0.69 (0.38–1.28) 0.2
 LH MoM (> 32 mm) 0.65 (0.46–0.92) 0.88 (0.62–1.24) 0.5 0.80 (0.53–1.21) 0.93 (0.61–1.42) 0.8
 SH MoM (≤ 32 mm) 0.55 (0.36–0.85) 0.85 (0.55–1.32) 0.5 0.59 (0.33–1.08) 0.79 (0.43–1.43) 0.4
HR: hazard ratio. See Table 1 for other abbreviations.
a Men: Heart failure hospitalization – adjusted for (RxRisk-V) age, cement, arrhythmia, hypertension, ischemic heart disease angina, 
   and ischemic heart disease hypertension. Death – adjusted for (RxRisk-V) age and cement.
b Women: Heart failure hospitalization – adjusted for (RxRisk-V) age, arrhythmia, hypertension, and IHD hypertension.  Death – 
   adjusted for (RxRisk-V) age and cement.
c Note: Cause-specific hazard ratios censored for death, revision, and second hip. 
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MoM hips and patients with MoP hips, but we cannot rule out 
an association with these prostheses, as only a small number 
of each type of design and combination was used in the other 
MoM groups. There is large variability in femoral design, 
femoral head size, metallurgy, modularity, and acetabular 
components between implanted MoM prostheses, so revision 
rates and the potential for metal particle and ion production 
vary between MoM prostheses (Cheung et al. 2016).
We were unable to adjust for a number of potential con-
founding factors associated with heart failure events, such 
as tobacco and alcohol use, obesity, and pre-existing cardiac 
dysfunction (with preserved or reduced ejection fraction), but 
we did exclude patients who had been hospitalized previously 
for heart failure and those who were on medicines likely to 
be indicative of heart failure. These factors are unlikely to be 
associated with the type of prosthesis selected by the surgeon, 
so we have no reason to believe that this would systematically 
bias our results. Our cohort had a higher median age than the 
general population who received MoM prostheses, and one of 
the limitations of our study is that the results are generalizable 
only to an older patient population. We did adjust for age and 
baseline comorbidities using the validated comorbidity burden 
RxRisk-V; the hazard ratio for admission for heart failure fol-
lowing the use of the ASR XL rather than a MoP prosthesis was 
higher than for the unadjusted result (Table 3). Importantly, 
heart failure was not an identified risk at the time the treatment 
decision was made, so it is unlikely that patients were selected 
to receive a particular bearing surface due to this perceived risk. 
However, even if confounding by indication did occur, indica-
tions for MoM hips were for younger patients and so patients 
who received MoM hips would probably have a lower risk of 
developing heart failure than patients who received MoP hips. 
It might be expected that there would also be an increased mor-
tality risk. Our study population was an older cohort, and con-
sequently the mortality for all groups was high. This may be 
the explanation for no observed difference. It is also possible 
that longer follow-up may be required before any difference in 
mortality is observed. The observation that there was no statis-
tically significant difference in mortality between the exposure 
groups also indicates that the groups were not different in their 
overall health status at the time of their primary THA, suggest-
ing that the observed increase in heart failure rate was not due 
to selection of the ASR XL for sicker patients who were more 
at risk of experiencing this event. 
We used the endpoint of primary discharge diagnosis of 
heart failure to identify incident heart failure, which would 
mainly identify patients with the most severe heart failure. 
This approach may have underestimated the incidence of heart 
failure (Pfister et al. 2013), resulting in possible misclassifica-
tion of outcomes, but there is no reason to suspect that this 
miscalssification would differ between the exposure groups 
and would have introduced bias in our results. Our sensitivity 
analysis including both primary and secondary diagnoses of 
heart failure resulted in an increased proportion of heart fail-
ure outcomes, while estimates of relative hazards were similar 
to the main analysis. Because only a 1-year lookback period 
for a history of heart failure was used to exclude patients, it is 
possible that patients with a history of heart failure who were 
not on medication in the year prior to surgery were not cap-
tured. However, if the history of heart failure is under-ascer-
tained in our patients, we have no reason to believe that it was 
different between the patients with MoM and the patients with 
MoP—and it is unlikely to have biased our estimations.
Our study had a number of major strengths. The most impor-
tant was the quality of the data source. Veterans’ adminstrative 
health data in Australia are comprehensive, and have enabled 
the examination of a possible temporal relationship between 
undergoing THA and development of heart failure. Data are 
available for the type of hip replacement procedure, type of 
hip prosthesis, hospitalizations for heart failure, mortality, 
and dispensed medications. The comorbidities of the differ-
ent groups could be identified and compared using a validated 
comorbidity measure based on prescribed medicines (RxRisk-
V). The totality of the information available was important in 
avoiding potential bias and confounding in this analysis. 
In summary, our study shows that men with a ASR XL THA 
with no recorded history of heart failure at the time of surgery 
had a higher rate of hospital admission for heart failure fol-
lowing the THA than men with a MoP THA. Further studies 
are needed to investigate whether the association can also be 
found in a younger cohort of patients with these prostheses. 
While the causality of the relationship remains uncertain, our 
findings highlight an urgent need for further research to inves-
tigate this possibility. It may also have possible implications 
for the long-term monitoring of people who have received the 
ASR XL and possibly other MoM hip prostheses. 
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